Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.74 and last traded at $29.71, with a volume of 155066 shares trading hands. The stock had previously closed at $29.73.
Chugai Pharmaceutical Price Performance
The stock's 50 day moving average is $24.31 and its 200-day moving average is $23.02. The company has a market capitalization of $95.01 billion, a P/E ratio of 37.49 and a beta of 0.80.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. The company had revenue of $1.89 billion during the quarter. On average, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 EPS for the current year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Featured Stories
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
